Summary
A 2-part, Phase 2 controlled, open-label, randomized study in participants with platinum-resistant recurrent ovarian cancer. In Part 1, participants received SGI-110 and carboplatin. The optimum dose of SGI-110 (guadecitabine) was identified in Part 1 based on safety and efficacy. In Part 2, participants were randomized to receive the dose identified in Part 1 plus carboplatin or one of four treatment of choice at the discretion of the investigator. The treatment of choice consisted of topotecan, pegylated liposomal doxorubicin, paclitaxel or gemcitabine.
Key Facts
Lead Sponsor
Enrollment
Start Date
Completion Date
Study Type
Official Title
Interventions
Conditions
Eligibility
Age Range
Sex
Inclusion Criteria: 1. Participants who are women 18 years of age or older. 2. Participants who have histologically or cytologically confirmed recurrent high-grade serous epithelial ovarian cancer (Grade 2 or 3), primary peritoneal carcinomatosis or fallopian tube cancer. 3. Participants who have platinum-resistant disease (defined as having relapsed within 6 months of her last platinum-containing regimen). There is no limit on the number of prior treatment regimens in Part 1. In Part 2, participants may have had no more than 3 prior cytotoxic treatment regimens, excluding adjuvant or maintenance therapy. 4. Participants must have had prior paclitaxel treatment. 5. Participants who have measurable disease according to RECIST v1.1 or detectable disease. 6. Participants with ECOG performance status of 0 or 1. 7. Participants with acceptable organ function. 8. Participants must be at least 3 weeks from last chemotherapy. Exclusion Criteria: 1. Participants who have hypersensitivity to SGI-110 and/or carboplatin or other components of these drug products. 2. Participants who have received prior therapy with any hypomethylating agents. 3. Participants who are refractory to platinum treatment i.e., progressed while on platinum treatment. 4. Participants with abnormal left ventricular ejection fraction. 5. Participants with Grade 2 or greater neuropathy. 6. Participants with known brain metastases. 7. Participants with known history of HIV, HCV or HBV.